Trial Profile
A Multicenter Extension Study to Evaluate the Long-Term Safety and Durability of the Therapeutic Effect of LUM001, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 May 2023
Price :
$35
*
At a glance
- Drugs Maralixibat (Primary)
- Indications Alagille syndrome; Cholestasis; Liver disorders
- Focus Adverse reactions
- Acronyms IMAGINE-II
- Sponsors Mirum Pharmaceuticals; Shire; Takeda
- 19 May 2023 According to a Mirum Pharmaceuticals media release, integrated analysis of 2 studies presented at the 55th European Society for Pediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting.
- 05 Oct 2022 According to a Mirum Pharmaceuticals media release, a 4-year analysis data will be presented during the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting 2022.
- 24 Jun 2022 According to a Mirum Pharmaceuticals media release, data from this study presented at the 54th Annual European Society for Paediatric Gastroenterology, Hepatology, and Nutrition Annual Meeting (ESPGHAN)